News

Kris Kowdley, MD, Supported Research Leading to Accelerated FDA Approval of Gilead’s Livdelzi® for Primary Biliary Cholangitis

Another milestone for patients with primary biliary cholangitis (PBC) — Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, AGAF, FAASLD, FACP, FAC, was an author of the Phase 3 trial results published in the New England Journal of Medicine. Congratulations to Gilead, Dr. Kowdley, the team … Read more

An interview with Dr. Robert Cupelo on Alzheimer’s Treatment and the Legacy of Lecanemab

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply addressing the symptoms.  It was this type of breakthrough that Robert … Read more

Velocity appoints ICON exec Rachael Buck Ph.D. as Head of U.K.

Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the … Read more

Velocity Sites and Investigators Supported Research for Nine Products That Have Received FDA Approval in 2024

Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include, but are not limited to: Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved #MASH drug. Moderna’s mRESVIA, an mRNA RSV vaccine for adults 60 and older. Eli Lilly and Company’s Kisunla (donanemab) for patients with early … Read more

Mike Zaranek Joins Velocity as CFO

Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, today announces it has appointed Mike Zaranek as Chief Financial Officer (CFO). Reporting to Velocity President and CEO Paul Evans with immediate effect, Zaranek will direct the company’s financial goals and accounting, and advise on the Company’s strategic direction. Mike brings nearly three decades of … Read more

VISION Engage Reaches $1 Million in Patient Study Stipends Paid

Velocity has now paid more than $1.1 million in patient study stipends through our VISION Engage app. Here’s why this matters: Patients get: Prompt, secure in-app payments Direct bank transfers or virtual debit card options Enhanced visibility and flexibility Sites get: Seamless integration with existing workflows Reduced administrative burden Improved patient satisfaction and retention Explore … Read more

A Lean-Value Approach to Technical Product Management

Raghu Punnamraju, Chief Technology Officer at Velocity, was recently interviewed by CIO News about applying a lean-value approach to our technical product management, engineering, and architectural strategies. Through the development of our VISION platform, and new frameworks that leverage LLMs, this article details how Raghu and our team in Hyderabad, India, are continuously delivering solutions … Read more

The Importance of Diversity in Clinical Trials with Dr. Jerome Adams

The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments … Read more

Velocity Announces New Site in St. Louis, Missouri

Velocity has announced a new site in St. Louis, its first in Missouri. The site will be co-located with West County Rheumatology, one of the largest and most active infusion centers in the Midwest, and a region-leading clinic for patients with rheumatoid arthritis, psoriatic arthritis, lupus, fibromyalgia, and hypermobility disorders. An elected Fellow of the … Read more